abs241.txt	background		radical	cystectomy	is	the	surgical	standard	for	invasive	bladdercancer		robot-assisted	cystectomy	has	been	proposed	to	provide	similaroncological	outcomes	with	lower	morbidity		we	aimed	to	compare	progression-freesurvival	in	patients	with	bladder	cancer	treated	with	open	cystectomy	androbot-assisted	cystectomy	methods		the	razor	study	is	a	randomised		open-label		non-inferiority		phase	3trial	done	in	15	medical	centres	in	the	usa		eligible	participants	(aged	≥18years)	had	biopsy-proven	clinical	stage	t1-t4		n0-n1		m0	bladder	cancer	orrefractory	carcinoma	in	situ		individuals	who	had	previously	had	open	abdominalor	pelvic	surgery		or	who	had	any	pre-existing	health	conditions	that	wouldpreclude	safe	initiation	or	maintenance	of	pneumoperitoneum	were	excluded	patients	were	centrally	assigned	(1	1)	via	a	web-based	system		with	blockrandomisation	by	institution		stratified	by	type	of	urinary	diversion		clinical	tstage		and	eastern	cooperative	oncology	group	performance	status		to	receiverobot-assisted	radical	cystectomy	or	open	radical	cystectomy	with	extracorporealurinary	diversion		treatment	allocation	was	only	masked	from	pathologists		theprimary	endpoint	was	2-year	progression-free	survival		with	non-inferiorityestablished	if	the	lower	bound	of	the	one-sided	97·5%	ci	for	the	treatmentdifference	(robotic	cystectomy	minus	open	cystectomy)	was	greater	than	-15percentage	points		the	primary	analysis	was	done	in	the	per-protocol	population	safety	was	assessed	in	the	same	population		this	trial	is	registered	withclinicaltrials	gov		number	nct01157676	findings		between	july	1		2011		and	nov	18		2014		350	participants	were	randomlyassigned	to	treatment		the	intended	treatment	was	robotic	cystectomy	in	176patients	and	open	cystectomy	in	174	patients		17	(10%)	of	176	patients	in	therobotic	cystectomy	group	did	not	have	surgery	and	nine	(5%)	patients	had	adifferent	surgery	to	that	they	were	assigned		21	(12%)	of	174	patients	in	theopen	cystectomy	group	did	not	have	surgery	and	one	(1%)	patient	had	roboticcystectomy	instead	of	open	cystectomy		thus		302	patients	(150	in	the	roboticcystectomy	group	and	152	in	the	open	cystectomy	group)	were	included	in	theper-protocol	analysis	set		2-year	progression-free	survival	was	72·3%	(95%	ci64·3	to	78·8)	in	the	robotic	cystectomy	group	and	71·6%	(95%	ci	63·6	to	78·2)	inthe	open	cystectomy	group	(difference	0·7%		95%	ci	-9·6%	to	10·9%	pnon-inferiority=0·001)		indicating	non-inferiority	of	robotic	cystectomy	adverse	events	occurred	in	101	(67%)	of	150	patients	in	the	robotic	cystectomygroup	and	105	(69%)	of	152	patients	in	the	open	cystectomy	group		the	most	commonadverse	events	were	urinary	tract	infection	(53	[35%]	in	the	robotic	cystectomygroup	vs	39	[26%]	in	the	open	cystectomy	group)	and	postoperative	ileus	(33	[22%]in	the	robotic	cystectomy	group	vs	31	[20%]	in	the	open	cystectomy	group)	interpretation		in	patients	with	bladder	cancer		robotic	cystectomy	wasnon-inferior	to	open	cystectomy	for	2-year	progression-free	survival		increasedadoption	of	robotic	surgery	in	clinical	practice	should	lead	to	future	randomisedtrials	to	assess	the	true	value	of	this	surgical	approach	in	patients	with	othercancer	types	funding		national	institutes	of	health	national	cancer	institute	
